APT Therapeutics
This article was originally published in Start Up
Executive Summary
Current public genomic information has dramatically simplified the identification of novel proteins. An immediate challenge exists, however, to predict the precise function of these proteins. APT Therapeutics Inc. has developed technologies to address this hurdle, with an initial goal of using these tools to prioritize candidates for preclinical validation. In addition, it has acquired significant expertise in optimization of protein expression and preclinical production.